<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03606629</url>
  </required_header>
  <id_info>
    <org_study_id>SC-SO-001</org_study_id>
    <nct_id>NCT03606629</nct_id>
  </id_info>
  <brief_title>SOLARIS Endoprosthesis in Iliac Occlusive Disease</brief_title>
  <acronym>SOLARIS I</acronym>
  <official_title>Solaris Endoprosthesis Performance in Treatment of Patients With Peripheral Occlusive Arterial Disease in the Iliac Territory - Post-Marketing Solaris I Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scitech Produtos Medicos Ltda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scitech Produtos Medicos Ltda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fifty patients will be treated with Solaris Endoprosthesis and followed up to 2 years with
      Walking Impairment Questionnaire and Doppler Ultrasound evaluation in 30 days, 6 months and
      12 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Events</measure>
    <time_frame>1 day</time_frame>
    <description>MAE is defined as death related to study device/ procedure, Myocardial Infarction, Target Vessel Revascularization or member amputation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Target Lesion Patency</measure>
    <time_frame>6 months</time_frame>
    <description>Stenosis &lt; 50% and systolic velocity up to 2.5 cm2/s and no TLR</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Endoprosthesis implantation</arm_group_label>
    <description>Device implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endoprosthesis implantation</intervention_name>
    <description>Endoprosthesis implantation by Percutaneous Angioplasty</description>
    <arm_group_label>Endoprosthesis implantation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with POAD presenting limitant intermitent claudication after 6 months of clinical
        treatment and patients with rest ischemia, Rutherford class 2 to 5.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rutherford Class 2 to 5;

          -  Tasc II Class A, B, C or D;

          -  Unilateral or bilateral lesion, de novo or restenotic but not in-stent;

          -  Target lesion of 3 to 10 cm length;

          -  ≥ 50% stenosis or common iliac or external iliac artery;

          -  Reference vessel diameter ≥ 5 and ≤ 9 mm;

          -  Deep femoral artery patent and at least one infrapopliteal artery patent;

          -  Informed Consent provided.

        Exclusion Criteria:

          -  Thrombocytopenia induced by heparina or tPA intravenous, clopidogrel, ticlopidine or
             aspirin sensitivity;

          -  Target lesion near to aneurysm, highly calcified or excessively tortuous;

          -  Previous stent on target vessel;

          -  Presence of other lesions that need treatment within 30 days;

          -  Rutherford Class 6;

          -  Acute thrombotic occlusion;

          -  History on amputation on the target limb.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luiz Furuya, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Santa Casa de Misericórdia de Santo Amaro</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juliana Castro, PhD</last_name>
    <phone>+55 11 21258900</phone>
    <email>jcastro@scitechmed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juliana Castro</last_name>
    <phone>+55 11 21258900</phone>
    <email>jcastro@scitechmed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Clínicas de Passo Fundo</name>
      <address>
        <city>Passo Fundo</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mateus Correa, MD</last_name>
      <email>mateuspc@msn.com</email>
    </contact>
    <investigator>
      <last_name>Mateus P Correa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>July 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>May 9, 2019</last_update_submitted>
  <last_update_submitted_qc>May 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

